- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Daiichi Sankyo to Cut 1200 US Jobs
October 19, 2015.
Daiichi Sankyo will "reorganize its U.S. Commercial organization as it transfers to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology", the company has announced.
The company says it "will reduce expenses, including a reduction in headcount, from its U.S. Commercial operations". It expects to eliminate 1,000 to 1,200 positions across the country, from the Commercial Home Office, located in Parsippany, NJ, and field-based sales and other positions throughout the country. The company added that the reorganization is not focused on the U.S.-based R&D function concentrated in Edison, NJ, or the packaging plant in Bethlehem, PA.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
